| Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorates joint swelling in established monkey collagen-induced arthritis. | |
| | |
MedLine Citation:
|
PMID: 18520048 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
We examined if tocilizumab, humanized anti-interleukin-6 receptor (IL-6R) antibody, can ameliorate joint swelling after the onset of arthritis in collagen-induced arthritis (CIA). CIA was induced by the immunization of bovine type II collagen in female cynomolgus monkeys. Tocilizumab (30 mg/kg) was administered weekly for 4 weeks after the onset of arthritis. Swelling of 16 proximal interphalangeal (PIP) joints of hands and feet was monitored by measuring the longitudinal and transverse axes of PIP joints and the oval area of each PIP was calculated. Serum was collected once a week after tocilizumab injection and blood chemistry, IL-6, soluble IL-6R (sIL-6R), and anti-tocilizumab antibody were measured. At the end of study, histopathological examination of joints was performed. Tocilizumab clearly reduced joint swelling in all animals without anti-tocilizumab antibody. Histopathological study showed significant decrease in the infiltration of neutrophils into inflamed joints was observed in tocilizumab-treated animals. In conclusion, tocilizumab improved established arthritis in monkey and monkey CIA model is useful for the analysis of anti-arthritic effect of tocilizumab. |
| | |
Authors:
|
Yasushi Uchiyama; Keigo Yorozu; Misato Hashizume; Yoichiro Moriya; Masahiko Mihara |
Related Documents
:
|
16078498 - Examination of spur marks found on inkjet-printed documents. 12713008 - Merlin pryce (1902-1976) and penicillin: an abiding mystery. 13677378 - Clinical characteristics and endoscopic findings associated with blastocystis hominis i... 6046048 - Project head start. an evaluation of the medical components in california. 9217518 - Organizational models of medical school relationships to the clinical enterprise. 12577988 - Alauddin qarshi: a commentator of many classical treatises. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Biological & pharmaceutical bulletin Volume: 31 ISSN: 0918-6158 ISO Abbreviation: Biol. Pharm. Bull. Publication Date: 2008 Jun |
Date Detail:
|
Created Date: 2008-06-03 Completed Date: 2008-06-30 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9311984 Medline TA: Biol Pharm Bull Country: Japan |
Other Details:
|
Languages: eng Pagination: 1159-63 Citation Subset: IM |
Affiliation:
|
Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Anti-Inflammatory Agents, Non-Steroidal* Antibodies / blood Antibodies, Monoclonal / immunology, pharmacology* Arthritis, Experimental / chemically induced, drug therapy*, pathology Biological Markers C-Reactive Protein / biosynthesis Collagen Type II* Edema / pathology, prevention & control Female Foot / pathology Hand / pathology Interleukin-6 / blood Joints / pathology Macaca fascicularis Neutrophil Infiltration / drug effects Receptors, Interleukin-6 / antagonists & inhibitors*, immunology* |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Inflammatory Agents, Non-Steroidal; 0/Antibodies; 0/Antibodies, Monoclonal; 0/Biological Markers; 0/Collagen Type II; 0/Interleukin-6; 0/Receptors, Interleukin-6; 0/tocilizumab; 9007-41-4/C-Reactive Protein |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: In vivo antitumor activity of novel water-soluble taxoids.
Next Document: Differential contribution of spinal mitogen-activated protein kinases to the phase of long-lasting a...